孟鲁司特钠治疗小儿轻中度持续性哮喘疗效观 察

目的探讨孟鲁司特钠治疗小儿中轻度持续性哮喘的临床疗效。方法选取来该院进行治疗的轻中度持续性哮喘患儿80例．随机分为两组，对照组40例患儿给与布地奈德气雾剂进行治疗，观察组40例患儿在对照组治疗的基础上，再给予口服孟鲁司特钠片进行治疗。结果观察组患儿的临床总有效率为95．0％，对照组患儿的临床总有效率为77．5％，两者比较差异有统计学意义（P〈0．05）。治疗后，观察组患儿的肺功能改善状况显著优于对照组患儿，比较差异有统计学意义（P〈0．05）。治疗后观察组患儿的嗜酸粒细胞和血清IgE水平均显著低于对照组患儿，比较差异有统计学意义（P〈0．05）。两组患儿在治疗过程中均未出现任何不良反应。结论孟鲁司特钠治疗小儿轻中度持续性哮喘具有临床效果显著、不良反应较低、安全性高的优点值得推广应用。

Observation on the Efficacy of Montelukast Sodium in the Treatment of Children with Mild or Moderate Persistent Asthma

Objective To study the clinical curative effect of Montelukast Sodium in the treatment of patients with mild or moderate persistent asthma. Methods 80 cases of children with mild or moderate persistent asthma admitted in our hospital were selected and randomly divided into two groups, 40 cases in the control group were given Budesonide Aerosol treatment, and 40 eases in the ob- servation group were given Montelukast Sodium Tablets orally on the basis of Budesonide Aerosol treatment. Results The clinical total effective rate of the observation group was 95.0%, while that of the control group was 77：5%, the difference is statistically Jig- nificant （P〈0.05）. After treatment, the lung function of the children in the observation group improved much better than that of the children in the control group, the difference was statistically significant （/~〈0.05）; The acidophilic granulocyte alad serum IgE levels of the chil- dren in the observation group were obviously lower than those of the children in the control group, the differences were statistically significant （P〈0.05）. And no adverse reactions occurred in both groups during the treatment. Conclusion Montelukast Sodium has the advantages of significant clinical effect, low adverse reactions and high safety in the treatment of children with mild or moderate persistent asthma, which is worthy of popularization and application.